During the past decade, Pusan National University Yangsan Hospital conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 4 clinical trials were completed, i.e. on average, 10.8% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 4 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pusan National University Yangsan Hospital" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Pusan National University Yangsan Hospital" with 7 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored, "Pfizer" with 4 trials sponsored and "Amicus Therapeutics" with 4 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pusan National University Yangsan Hospital" #1 collaborator was "Ferring Pharmaceuticals Korea, Ltd." with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Everest Medicines" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Pusan National University Yangsan Hospital" are "Breast Cancer" (3 trials), "Prostate Cancer" (3 trials), "Urinary Bladder Neoplasms" (3 trials), "Gastric Cancer" (2 trials) and "Healthy" (2 trials). Many other conditions were trialed in "Pusan National University Yangsan Hospital" in a lesser frequency.

Most popular intervention types in "Pusan National University Yangsan Hospital" are "Drug" (28 trials), "Biological" (8 trials), "Other" (6 trials), "Device" (4 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Cetrelimab" (4 trials), "Atezolizumab" (3 trials), "TAR-200" (3 trials) and "AT2221" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pusan National University Yangsan Hospital" are 37 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Pusan National University Yangsan Hospital". undefined are not yet recruiting, 14 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Pusan National University Yangsan Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Pusan National University Yangsan Hospital, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".